


# **Maternal/Pediatric Respiratory Syncytial Virus (RSV) Work Group**

**Sarah S. Long, MD**  
**Chair, Maternal/Pediatric RSV Work Group**

**ACIP General Meeting**  
**October 20, 2022**



# Work Group Members

## ACIP Members

Sarah Long (chair)

Pablo Sanchez

Oliver Brooks

Camille Kotton

## Ex Officio Members

Rachel Zhang (FDA-CBER)

Nicholas Geagan (FDA-CBER)

Judy Beeler (FDA-CBER)

Yodit Belew (FDA-CDER)

Prabha Viswanathan (FDA-CDER)

Samer El-Kamary (FDA-CDER)

Sonnie Kim (NIH-NIAID)

April Killikelly (Public Health Agency of Canada)

Winnie Siu (Public Health Agency of Canada)

Valerie Marshall (OIDP/OASH)

Jessica Lee (CMS/CMCS)

Terry Dalle-Tezze (HRSA)

## Consultants

Cody Meissner (Tufts Medical Center)

Helen Chu (University of Washington)

Natasha Halasa (Vanderbilt University)

Denise Jamieson (Emory University School of Medicine)

Daniel Feikin (World Health Organization)

Carol Baker (University of Texas Health Science Center)

## Liaisons

James McAuley (IDSA)

Patsy Stinchfield (NFID)

Brenna L. Hughes (ACOG)

Nicole Chaisson (AAFP)

Sean O-Leary (AAP)

Jennifer Schuster (PIDS)

Molly Howell (AIM)

## GRADE/EtR consultants

Doug Campos-Outcalt

Rebecca Morgan

## CDC

Katherine Fleming-Dutra (co-lead)

Jefferson Jones (co-lead)

Meredith McMorrow

Mila Prill

Natalie Thornburg

Aron Hall

Ismael Ortega-Sanchez

Tamara Pilishvili

Tom Clark

Jamison Pike

Lauren Roper

Heather Scobie

Adam MacNeil

Amber Winn

Chris Taylor

Claire Midgley

Fiona Havers

Tami Skoff

Angie Campbell

Michael Melgar

# RSV is the leading cause of hospitalization in U.S. infants

- RSV can infect the small airways and lungs, particularly in infants
- Most (68%) infants are infected in the first year of life and nearly all (97%) by age 2<sup>1</sup>
- Premature infants born at <30 weeks gestation have hospitalization rates ~3x higher than term infants<sup>2</sup>
- 79% of children hospitalized with RSV aged <2 years have no underlying medical conditions<sup>2</sup>
- 2-3% of all infants are hospitalized for RSV<sup>2,3</sup>



Image: Goncalves et al. Critical Care Research and Practice 2012

<sup>1</sup>Glezen et al, Arch Dis Child, 1986; <sup>2</sup>Hall et al, Pediatrics, 2013; <sup>3</sup>Langley & Anderson, PIDJ, 2011

# Previous maternal/pediatric RSV ACIP presentations

- Epidemiology and burden of RSV in infants
  - RSV seasonality in United States
  - Outpatient, emergency department (ED) visits, hospitalizations, and deaths
- Virology
- Safety and efficacy of nirsevimab
  - Initial results from Phase 3 study in infants born  $\geq 35$  weeks gestation<sup>1</sup>
  - Phase 2b study in infants born 29–34 weeks gestation
  - Phase 2/3 safety and pharmacokinetic study in high-risk infants<sup>2</sup>

<sup>1</sup>Paused because of COVID-19 pandemic

<sup>2</sup>Eligible for palivizumab

# Agenda: Thursday October 20, 2022

- Nirsevimab updated safety and efficacy Dr. Christian Felter (Sanofi)
- WG considerations Dr. Jefferson Jones (CDC)

For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [www.cdc.gov](http://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

